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Acid-degradable cationic nanoparticles encapsulating a model antigen (i.e., ovalbumin) were prepared by inverse micro-
emulsion polymerization with acid-cleavable acetal cross-linkers. Incubation of these degradable nanoparticles with dendritic
cells derived from bone marrow (BMDCs) resulted in the enhanced presentation of ovalbumin-derived peptides, as quantified
by B3Z cells, a CD8+ T cell hybridoma. The cationic nature of the particles contributed to the increased surface endocytosis (or
phagocytosis) observed with BMDCs, which is the first barrier to overcome for successful antigen delivery. The acid sensitivity
of the particles served to direct more ovalbumin antigens to be processed into the appropriately trimmed peptide fragments and
presented via the major histocompatibility complex (MHC) class I pathway following hydrolysis within the acidic lysosomes. It
was also shown that adjuvant molecules such as unmethylated CpG oligonucleotides (CpG ODN) and anti-interleukin-10
oligonucleotides (AS10 ODN) could be co-delivered with the protein antigen for maximized cellular immune response.
D 2005 Elsevier B.V. All rights reserved.
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ported by Bristol-Myers Squibb as a Sponsoring Member and
Novartis Pharma as Supporting Member.to human health as one of the most effective tools in
preventing and treating fatal diseases. Traditionally,
either whole inactivated or live attenuated microor-
ganisms are injected, however, this method some-
times leads to side effects that range from mild to
unacceptable. Recently, purified or recombinated
macromolecules of pathogens, such as surface pro-
teins or polysaccharides, have been used increasingly
in clinical trials to minimize the possible side effects.
As additional knowledge of the workings of the
immune system on a molecular level is acquired,e 105 (2005) 199–212
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ment of highly efficient but safe vaccines for dis-
eases such as AIDS and cancers that have previously
eluded treatment via vaccination [1–3]. Cancer
immunotherapy has been identified as one of the
most plausible alternatives to conventional chemo-
therapy, radiotherapy, and surgery as it possesses
many unique advantages. These include highly spe-
cific delivery to targeted cells, memory to pre-
immuned diseases, and simple administrations (e.g.,
injection, inhalation of aerosol vaccine, and skin
patch) [4]. As more detailed information of the
mechanism of the disease becomes available, the
delivery of therapeutic molecules has become one
of the most important targets for the development of
a successful vaccination strategy.
Activation of the immune system by a vaccine
requires (i) the delivery of a sufficient amount of
antigen to antigen presenting cells (APCs, macro-
phages and dendritic cells), (ii) the controlled presen-
tation of antigen molecules to target immune cells
(CD4+ and/or CD8+ T cells), (iii) the proliferation of
effector cells such as cytotoxic T lymphocytes (CTLs)
and plasma B cells, and (iv) the maintenance of an
activated immune system for the desired period of
time [5]. However, no universal vaccine system dis-
playing all of these requirements has been developed
thus far. To deliver antigens to phagocytic APCs,
various delivery systems such as liposomes, micro-
particles, and nanotubes have been studied [6–8].
Using these delivery vehicles, the antigens mixed
with adjuvant molecules, such as bacterial lipopoly-
saccharide (LPS), have demonstrated prolonged im-
mune responses and increased local inflammation [9].
Once internalized, antigens are processed by either
an endogenous or an exogenous pathway. Endoge-
nous antigen-derived peptides are presented on
major histocompatibility complex (MHC) class I
molecules, which activate a cytotoxic T lymphocyte
(CTL)-mediated immune response, or cellular immu-
nity, after binding to T cell receptors. In contrast, an
antibody-mediated response, also referred to as hu-
moral immunity, is activated through exogenous anti-
gen-derived peptide/MHC II complexes on APCs.
Therefore, it is presumed that a desirable immune
response can be achieved by controlling the antigen
presentation pathway and cellular immune response
has been reported to be more effective in removinginfected cells and cancers than humoral immunity
[10]. In previous studies, it has been shown that an
increased MHC I antigen presentation can be achieved
by priming APCs with antigen-encapsulating acid-
degradable nanoparticles, which degrade at acidic
pH following phagocytosis to release the antigens
into the cytoplasm [11–13].
In this study, a model antigen, ovalbumin, was
encapsulated in cationic acid-degradable nanoparti-
cles. Incubation with the most potent professional
APCs, dendritic cells (DCs), resulted in an increased
endocytosis of the nanoparticles and presentation of
ovalbumin on MHC I molecules by DCs. It was also
shown that maximized immune responses might be
achieved simply by coating adjuvant oligonucleotides
on the cationic surface of the nanoparticles.2. Materials and methods
2.1. Preparation of acid-degradable cationic
nanoparticles
The degradable nanoparticles were prepared by an
inverse microemulsion polymerization method as fol-
lows. Non-ionic surfactants (3 :1 Span 80 :Tween 80,
Aldrich, St. Louis, MO), were dissolved in hexane at
the concentration of 10% (w:w), and air was removed
by sparging with dry nitrogen overnight. An aqueous
solution of monomers was prepared by dissolving
acrylamide (Biorad, Hercules, CA), 2-acryloxyethyl-
trimethylammonium chloride (AETMAC, Aldrich), 5
mg ammonium persulfate (APS, Biorad), and acid-
labile benzyl acetal cross-linker [13] in 200 AL of
phosphate buffered saline (PBS, pH 8.0) containing
10 mg/mL of ovalbumin (Sigma, St. Louis, MO). The
aqueous solution of monomers was combined with 20
mL of the organic surfactant solution. After vigorous-
ly shaking the mixture for 1 min, polymerization was
initiated by the addition of 20 AL of N,N,N´,N´-tetra-
methylethylenediamine (TEMED, Sigma). The mix-
ture was stirred for 10 min before adding an excess of
acetone (1.5–2 times the volume of the organic sur-
factant solution) to settle the clumped nanoparticles,
followed by an additional 10 min of gentle stirring.
After standing 1 h, the precipitated pellet was washed
once with acetone and dried under vacuum overnight.
By changing the ratio of AETMAC to acrylamide,
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fixed crosslinking ratio of 5%. For comparison,
non-degradable polyacrylamide nanoparticles were
made using acrylamide and N,N´-methylenebisacryla-
mide (Biorad).
2.2. Nanoparticle characterization
The size and surface charge of the nanoparticles
were measured using a dynamic light scattering (DLS)
particle sizer and zeta potential analyzer (Zetasizer
Nano ZS, Malvern Instruments, Malvern, UK). The
nanoparticles were suspended at 1 mg/mL in pH 7.4
PBS (Gibco BRL, Bethesda, MD) for the size mea-
surement and in pH 7.5 buffer made of 5 mM HEPES
and 1 mM NaCl for zeta-potential analysis. For trans-
mission electron microscopy (TEM), the nanoparticle
suspension in PBS was spotted onto a formvar/carbon
grid (Ted Pella, Redding, CA). After 5 min the grid
was washed with distilled water twice and then dried
at room temperature for 2 h. To minimize hydrolysis
of the particles, the samples were examined immedi-
ately after drying with a Philips Tecnai 12 transmis-
sion electron microscope with 100 kV. The diameters
of 100 randomly chosen nanoparticles were estimated
from the TEM image by using NIH Image (version
4.02, NIH, Bethesda, MD). The amount of protein
encapsulated was determined using ovalbumin that
had been conjugated with pH-insensitive cascade
blue dye (Molecular Probe, Eugene, OR). The labeled
protein was prepared according to the protocol pro-
vided by the manufacturer. The particles were hydro-
lyzed by incubating with 300 mM acetic acid buffer
pH 5.0 for 3 h at room temperature. Ovalbumin con-
centrations were quantified by measuring the cascade
blue fluorescence, obtained by exciting the solutions
at 355 nm and detecting the emitted 405 nm wave-
length using a fluorescence plate reader.
2.3. Bone marrow-derived dendritic cells (BMDCs)
Dendritic cells were obtained using a slightly mod-
ified literature procedure [14]. Briefly, femurs and
tibia of 2–4 month old female C57BL/6 mice (Jackson
Laboratory, Bar Harbor, ME) were extracted after
euthanasia, and the bone marrow was flushed out
using a 26 gauge needle with 5 mL of RPMI1640
medium supplemented with 10% (v/v) fetal bovineserum (FBS) (Hyclone, Logan, UT), 100 U/mL pen-
icillin, 100 Ag/mL streptomycin, 2 mM l-glutamine, 1
mM sodium pyruvate, and 55 AM 2-mercaptoethanol
(all from Gibco). After the red blood cells were re-
moved by treating with RBC lysis buffer (Gentra
Systems, Minneapolis, MN), the remaining cells
were cultured with the medium given earlier and
further supplemented with 5% (v/v) of granulocyte-
macrophage colony stimulating factor (GM-CSF)-
containing supernatant, a generous donation from
Dr. Edward James (UC Berkeley) [15]. After 7 days
of cultivation in a 6-well plate, the suspended cells
were inoculated onto a 96-well plate in the density of
5104 cells/well.
2.4. Antigen presentation assay
The amount of presented ovalbumin-derived pep-
tide OVA258–265 (or SIINFEKL) with MHC class I
molecule (Kb) was measured by an in vitro cellular
assay and an immunoassay. BMDCs were incubated
with varying amounts of ovalbumin-loaded nanopar-
ticles for 6 h and then washed extensively with pH
7.4 PBS. B3Z CD8+ T cell hybridomas (1105 cells/
well) were co-incubated overnight with BMDCs.
This hybridoma expresses lacZ upon binding of the
T cell receptor (TCR) to SIINFEKL/Kb [16]. The
medium was replaced with 100 AL of CPRG buffer
containing 91 mg of chlorophenol red h-D-galacto-
pyranoside (CPRG, Roche, Indianapolis, IN), 1.25
mg of NP40 (EMD Sciences, La Jolla, CA), 9 mL
of 1 M MgCl2 (Aldrich), and 1 L of PBS. The
amount of the lacZ enzyme was quantified by the
hydrolysis of CPRG, which produces chlorophenol
red absorbing at 595 nm. The quantity of SIINFEKL/
Kb was calculated by comparison with the UV ab-
sorption values obtained from free SIINFEKL pep-
tide incubated with DCs as a reference. To minimize
the pH drop that might result from lactic acid accu-
mulation, particles were added in fresh medium and
incubated with DCs for 1 and 6 h for the particle
uptake and antigen presentation experiments, respec-
tively. No change in color of the medium was ob-
served during these experiments suggesting that no
significant pH change had taken place since a slight
pH drop would have turned the medium yellow
(since phenol red works at very narrow range of
pH 6.4–8.0).
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the BMDC surface, 1106 cells were cultured on 2.2
cm round collagen I-coated coverslips (BD Bios-
ciences, Bedford, MA) in one well of a 6-well plate
and incubated with 0.5 mg of the nanoparticles in 2
mL of medium for 6 h. After washing with PBS twice,
the cells were fixed with 1% paraformaldehyde buffer,
followed by washing with PBS+5% FBS. Cells were
further incubated for 1 h at 4 8C with a 25-D1.16
monoclonal antibody (mAb) supernatant produced
from B cell hybridoma, which was gifted from Dr.
Ronald Germain (NIAID, NIH, Bethesda, MD) [17].
After washing with PBS+5% FBS, 1 Ag of R-phy-
coerythrin(PE)-conjugated goat anti-mouse polyclonal
antibody (Pharmingen, San Diego, CA) was added in
1 mL of PBS+5% FBS, and the cells were incubated
for an additional hour at 4 8C. After washing twice,
the coverslip was placed on a glass slide and exam-
ined using a LS450 laser-scanning confocal micro-
scope (Carl Zeiss, Thornwood, NY).
2.5. Endocytosis and cytotoxicity assay
Ovalbumin was conjugated with fluorescein-like
pH-insensitive Alexa Fluor 488 succinimidyl ester
(Molecular Probes). BMDCs were incubated with
0.5 mg of labeled ovalbumin-loaded nanoparticles
per well of a 6-well plate for 1 h, washed, trypsinized,
and analyzed using a Beckman-Coulter EPICS XL-
MCL flow cytometer. The kinetics of endocytosis by
BMDCs were determined by examining the mean
channel value, which is the average fluorescence in-
tensity above threshold level (i.e., fluorescence by
untreated cells as a reference). To test for cytotoxicity,
5104 BMDCs per well of a 96-well plate were
incubated with various amounts of acid-degradable
cationic nanoparticles for 6 h. After extensively wash-
ing three times with the medium, the cells were
cultured for additional 48 h. The medium was aspi-
rated, and 10 AL of a stock solution containing 10 mg/
mL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT, Sigma) in PBS was added
along with 90 AL of medium, followed by further
incubation for 3 h at 37 8C. The reduced MTT-for-
mazan product generated by live cells was dissolved
in 200 AL of dimethylsulfoxide, and 20 AL of glycine
buffer (0.1 M glycine, 0.1 M NaCl, pH 10.5) was
added. Relative viability of the cells incubated withnanoparticles to untreated cells was determined by
measuring the MTT-formazan absorbance at 561 nm.
2.6. Nucleic acid-coated nanoparticles
Immunostimulatory unmethylated CpG oligonucle-
otide (CpG ODN) 5V TCCATGACGTTCCTGACGTT
3V [18] and anti-IL-10 oligonucleotide (AS10 ODN) 5V
CATTTCCGATAAGGCTTGG 3V [19] were synthe-
sized using an Expedite 8909 DNA synthesizer (Ap-
plied Biosystems, Foster City, CA). A solution of 10 Ag
of CpGODN in 0.5 mL of PBS was mixed with 0.5 mL
of 10% cationic ovalbumin-encapsulating nanoparti-
cles (0.5 mg/mL) and incubated on ice for 10 min
with periodic mixing. The nanoparticles were washed
by resuspending in 1 mL of the medium after centrifu-
gation at 14,000 rpm for 30 s twice. A solution of 100
AL of the resuspended nanoparticles in the mediumwas
added per well of a 96-well plate, where 5104
BMDCs had been inoculated the day prior. AS10
ODN (20 AM) was adsorbed in the same manner as
for CpG ODN. After 24 h of cultivation, the amount of
interleukin-12 (IL-12) and IL-10 produced was quan-
tified using an enzyme-linked immunosorbent assay
(ELISA) kit (Pierce, Rockford, IL).
2.7. Data analysis
Data were obtained in triplicate unless otherwise
mentioned and are presented as meanF standard de-
viation, and further statistically analyzed by the stu-
dent t-test on the significance level of p b0.05.3. Results
3.1. Synthesis of cationic nanoparticles degradable at
lysosomal pH
The acid-degradable cationic nanoparticles were
synthesized by inverse microemulsion polymerization
of acrylamide 1, quaternary amine monomer AET-
MAC 2, and acid-labile acetal cross-linker 3 using a
modification of the method reported previously
[11,12] (Fig. 1). The microemulsion was achieved
by vigorous shaking instead of sonication, as the latter
may potentially damage the encapsulated molecules.
Since it was found that particles pelleted by centrifu-
Table 1
Formulation of various acid-degradable nanoparticles and ovalbu-
min encapsulation efficiency
Cationic ratio
[x / (x+y)](%)a
Encapsulation efficiency
(Ag ovalbumin/mg nanoparticles)
0 32.34F0.35
5 43.88F1.91
10 40.60F3.81
20 29.32F0.10
a Fixed crosslinking ratio [z / (x+y+z)]=5%.
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Fig. 1. Preparation of cationic acid-degradable nanoparticle by polymerization of acrylamide and a cationic monomer with cleavable acetal
cross-linker. Under the acidic conditions found in the lysosome, the cross-linkers are cleaved thus releasing the encapsulated antigens.
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ous solutions, the nanoparticles were harvested by
precipitation using gravity only. After treating with
acetone, the surfactants present on the surface of the
particles were washed away and the cationic surfaces
were exposed to non-polar hexane solvent. Following
settling of visible clumps of aggregated particles a
second acetone wash was performed to remove the
proteins on the surface of the particles. The degree of
cationic surface charge was easily manipulated by
varying the ratio of acrylamide to AETMAC mono-
mers (Table 1). Although increased antigen presenta-
tion has been achieved using acid-degradable
particles, and facilitated internalization of cationicmolecules has also been reported. This study is, to
our knowledge, the first to explore the simultaneous
realization of both of these major goals.
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nanoparticles
The size of various cationic and neutral nanoparti-
cles in PBS was measured using dynamic light scat-
tering. Regardless of the cationic monomer ratio, the
DLS results showed that the size of particles ranged
between 180–230 nm in diameter (Fig. 2a), which
bridges the size regimes for pinocytosis and phago-
cytosis [20]. Transmission electron microscopy
(TEM) also confirmed the size distribution, giving
an average diameter of 217F49 nm (Fig. 3). There-
fore, the particles are expected to be taken up exclu-0
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Fig. 2. Analysis of cationic acid-degradable nanoparticles: (a) size
(Z-average) measured by dynamic light scattering particle sizer with
the polydispersity index (PDI) given above each bar; (b) surface
charge by zeta-potential analyzer.
Fig. 3. Transmission electron micrograph of the nanoparticles made
with 10% cationic monomer (% with respect to acrylamide). Nano-
particles with different formulations also showed the similar size
distribution. The scale bar represents 1 Am.sively by phagocytic cells (e.g., macrophages and
dendritic cells) in a size-dependent passive targeting.
Since a reduced uptake of latex particles larger than
280 nm by DCs was reported previously [21], the
smaller particles prepared here can be efficiently
taken up by DCs. Although particles with 10% and
20% cationic monomer displayed a slightly smaller
diameter, the content of cationic monomer did not
significantly affect particle size distributions (Fig.
2a). A similar size distribution was observed with
non-degradable nanoparticles prepared in similar fash-
ion. As expected, zeta potential, or relative positive
charge density, increased as the ratio of cationic
monomer to acrylamide was increased (Fig. 2b).
Antigen payload was determined by hydrolysis of
the acid-degradable nanoparticles containing encapsu-
lated cascade blue labeled-ovalbumin. The highest
ovalbumin payloads were achieved with particles pre-
pared with 5% and 10% cationic monomers, resulting
in encapsulation efficiencies of 43.88 and 40.60 Ag/
mg, respectively (Table 1). Neutral and 20% cationic
acid-degradable nanoparticles exhibited 25% lower
encapsulation efficiencies compared to the 5% and
10% cationic nanoparticles. The amount of encapsu-
lated proteins in non-degradable particles cannot be
determined using the method used with degradable
particles (due to the lack of degradability of the
former). Spectroscopic data obtained with the non-
degradable and degradable particle solutions after
incubation in NaOH solution were very close. This
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comparable in the non-degradable and the degradable
particles.
3.3. Enhanced antigen presentation on MHC class I
by DCs using acid-degradable nanoparticles
For effective CTL activation, antigens must be
presented by MHC I molecules carrying the antigen-
derived peptides that have been processed in the
cytoplasm. To determine if the acid-degradability of
the particles increases the release of encapsulated
protein into the cytosol and, hence, increases antigen
presentation by MHC I, acid-degradable and non-
degradable particles with various cationic ratios
were prepared and incubated with BMDCs. The rela-
tive amounts of ovalbumin-derived peptide SIIN-
FEKL with Kb (MHC I) presented by BMDCs were
quantified by cultivation with the B3Z hybrima T cell
line. Overall, more SIINFEKL peptides were pre-
sented with MHC I after delivery in acid-degradable
nanoparticles than in non-degradable ones (Fig. 4).
Therefore, acid-degradability aids in the release of
ovalbumin into the cytoplasm, where proteins are
cleaved by proteasomes, and integrated with MHC
I in the endoplasmic reticulum (ER). This is because
it is thought that the particles are taken up by APCs
through phagocytosis then transferred to the acidic
lysosome. The acid sensitivity of the cross-linker
holding the particles together not only helps to re-0
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Fig. 4. Antigen presentation by BMDCs incubated with ovalbumin-encapsu
various cationic ratios.lease protein from the particle, but also their delivery
to the cytoplasm [12]. Ovalbumin encapsulated in
non-degradable particles is expected to be released
more slowly and would therefore be more suscepti-
ble to degradation by the proteases present in the
lysosome.
More peptides were presented when delivered in
neutral acid-degradable nanoparticles at high concen-
tration (i.e., 250–500 Ag/well), while 10% and 20%
cationic nanoparticles were more effective in antigen
delivery and presentation at lower concentrations (25–
50 Ag/well). The 10% cationic nanoparticles showed
the highest efficiency of SIINFEKL presentation on
Kb at the concentration of 50 Ag/well (Fig. 4a). The
lowest antigen presentation—even lower than with
neutral particles—was observed with 5% cationic
nanoparticles, at the concentrations of 5–50 Ag/well.
No detectable antigen presentation was seen using
20% cationic nanoparticles at the concentration of
250 Ag/well, whereas the neutral particles showed
maximum presentation at this same concentration
(Fig. 4a). With non-degradable nanoparticles, antigen
presentation levels were higher for cationic particles
than for neutral particles at concentrations of 5–50 Ag/
well (Fig. 4b). The maximum antigen presentation for
non-degradable particles was achieved by using 10%
cationic particles at the concentration of 50 Ag/well, as
was the case with the acid-degradable particles. Thus
it appears that 10% cationic acid-degradable nanopar-
ticles used at the concentration of 50 Ag/well consti-0
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lating (a) acid-degradable and (b) non-degradable nanoparticles with
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BMDCs.
Staining BMDCs with SIINFEKL/Kb-specific
mAbs clearly showed an increase in antigen presen-
tation using the acid-degradable nanoparticles (Fig.
5). Without particles, the cells themselves exhibit a
minimal amount of autofluorescence (Fig. 5a). Encap-
sulation of ovalbumin in acid-degradable particles
increases the signal observed by the fluorescent anti-
body, indicative of a higher concentration of SIIN-
FEKL peptides being presented at the cell surface.
The highest fluorescence signal was observed when
the BMDCs were exposed to 10% acid-degradable
cationic nanoparticles rather than neutral particles
(Fig. 5c). These results correlates with the antigen
presentation data given in Fig. 4, in which the 10%
cationic particles also exhibit a higher presentation
than the neutral particles at the concentration of 50
Ag/well.
3.4. Increased endocytosis of cationic nanoparticles
To assess the usefulness of the cationic carriers for
enhanced cellular uptake, cationic and neutral acid-
degradable nanoparticles encapsulating ovalbumin la-
beled with pH-insensitive fluorescent dye Alexa Fluor
488R were incubated with BMDCs for 1 h, followed
by flow cytometry analysis. Cells incubated with
cationic nanoparticles showed a higher fluorescence
intensity, indicative of more internalized particles,
than the cells incubated with neutral nanoparticles
(Fig. 6). Some of the cells (~20%) incubated with
neutral nanoparticles showed higher fluorescence(a) (b)
Fig. 5. Laser-scanning confocal micrographs of BMDCs stained with SIIN
(a) without nanoparticles, (b) with ovalbumin-encapsulating acid-degrad
nanoparticles for 6 h (magnification of 800).than the others, possibly an artifact of the polydisper-
sity of the particles. The cells that take up larger
particles, most likely containing more of the fluores-
cent ovalbumin, showed higher fluorescence intensity
(see the arrow on Fig. 6a). The particle uptake kinetics
showed that increased endocytosis of cationic nano-
particles occurred throughout the incubation period of
1 h (Fig. 6c). The fluorescence reached a plateau after
1 h because all of the protein had been processed.
Typically, an antigen is degraded and processed inside
a cell within a timeframe of 0.5–3 h. The saturation of
uptake corresponding to the plateau in fluorescence
might be mainly due to the balance between the
endocytosis and antigen processing. It should be
noted that the fluorescence measurements gave similar
results when performed after 1 h with gentle mixing
every 15 min (data not shown).
3.5. Cytotoxicity of cationic nanoparticles
At high concentration of acid-degradable nanopar-
ticles, decreased antigen presentation was observed,
as shown in Fig. 4. This result could be due to the
cationic nature of the particles. Cationic delivery
vehicles such as polyethyleneimine (PEI) and poly-
l-lysine (PLL) have been shown to inhibit cellular
viability and proliferation, even though they are effi-
ciently taken up by cells [22]. To determine the tox-
icity of our delivery system, acid-degradable cationic
nanoparticles were incubated with BMDCs for 6 h,
and the relative viability was quantified using the
conventional MTT assay. Results showed that the
cytotoxicity of the nanoparticles increases with con-(c)
FEKL/Kb specific monoclonal 25.D1-16 antibodies after incubated
able neutral nanoparticles, and (c) acid-degradable 10% cationic
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Even 20% decreased viability was observed with
neutral nanoparticles at the highest concentration of
500 Ag/well, where antigen presentation was dramat-
ically decreased (Fig. 4a). Possible explanations for
the observed cytotoxicity of neutral acid-degradable
nanoparticles include: (i) the existence of a threshold
amount of particles that can be processed without
retarding cellular proliferation; (ii) the intrinsic toxic-
ity of polyacrylamide in the cell; and (iii) the cyto-
toxicity of the benzaldehyde released after hydrolysis.
The 10% and 20% cationic nanoparticles, especially
the 20% sample, showed significant cytotoxicity at
the concentrations of 250 and 500 Ag/well (Fig. 7)
with decreased antigen presentation (Fig. 4a). How-
ever, at the concentration of 50 Ag/well, comparable
cytotoxicity of neutral and 10% cationic nanoparticles
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showed significantly lower proliferation. Given these
toxicity and antigen presentation studies, the most
efficient cationic delivery system at a reasonably ac-
ceptable concentration appears to be that with 10%
cationic monomer at a concentration of 50 Ag/well
equivalent to 0.25 mg/mL. These particles displayed
the highest antigen presentation (Fig. 4a), with high
proliferation (Fig. 7), and a more efficient uptake due
to the positive surface charge (Figs. 5c and 6).
3.6. Cytosolic release and DC maturation by degrad-
able nanoparticles
In order to visualize the fate of the proteins taken
up in the lysosomal compartment and their eventual
release into the cytoplasm, DCs were incubated with
fluorescently labeled nondegradable and acid-degrad-
able 10% cationic nanoparticles. As can be seen in
Fig. 8, the intracellular fate of the two different types
of nanoparticles was quite different. Ovalbumin fluor-
escently labeled with Alexa Fluor 488R, then encap-
sulated and delivered via nondegradable particles was
observed to remain confined within a restricted intra-
cellular area (Fig. 8a, dark arrow). In contrast fluores-
cence was observed throughout the cells incubated
with labeled acid-degradable particles (Fig. 8b). It
was also noticed that nondegradable particles tended
to form aggregates, which were not observed with
degradable particles (Fig. 8a, white arrow). This is
because the degradable particles made with the tetra-
glyme-conjugated cross-linkers possess enhanced dis-
persibility as reported previously [13].(a) (
Fig. 8. Combined differential interface-contrast (DIC) and laser-scannin
nondegradable (a) and acid-degradable nanoparticles (b) for 6 h. IntracellThe morphologies of BMDCs incubated with 10%
cationic nondegradable or degradable particles indi-
cated a very unexpected effect of the particle degrad-
ability on DC maturation (Fig. 8). Immature DCs are
specialized in antigen capture whereas mature DCs
present degraded peptides with upregulated MHC II,
and costimulatory and adhesion molecules. One of the
typical features of mature DCs is the unique morphol-
ogy with long and thin dendrites, which are thought to
be advantageous for maximizing antigen presentation
and T cell junctions. Very interestingly, BMDCs in-
cubated with 10% cationic degradable nanoparticles
displayed a highly dendritic surface (Fig. 8b), while
similar dendritic cells incubated with 10% cationic
nondegradable particles showed an immature stellate
shape (Fig. 8a). This observation suggests that degrad-
able particles enhance antigen presentation not only
by releasing encapsulated proteins into the cytoplasm
but also by triggering DC maturation. Although lyso-
somal disruption by acid-degradable particles seems
to cause BMDC maturation, a mechanism for this
event is not clear at this time. Obviously, DC matu-
ration would constitute another advantage for the use
of acid-degradable vaccine carrier as a result of such
enhanced immune activation.
3.7. Delivery of CpG and anti-IL-10 oligonucleotides
for maximized immune response
DCs bridge the innate nonspecific immune system
and the highly specific adaptive immunity through
several mechanisms, one of which is mediated by
Toll like receptors (TLR) that recognize unique mo-b)
g confocal micrographs of BMDCs incubated with 10% cationic
ular particle location was confirmed by varying focus planes.
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pathways required to functionalize the immune
responses. Immunostimulatory unmethylated CpG
ODN was coated on the acid-degradable 10% cationic
nanoparticles and incubated with BMDCs for 24 h.
Activation of the DCs was then quantified by IL-12
secretion, which polarizes CD4+ T helper cell type 1
(TH1) differentiation rather than TH2 and eventually
assists in CTL activation. Fig. 9a clearly illustrates
that BMDCs produced at least 10 times more IL-12
after incubation with CpG ODN-coated acid-degrad-
able nanoparticles than controls of cells alone,
BMDCs incubated with free CpG ODN, or the nano-
particles without CpG ODN. Similarly, AS10 ODN0
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Fig. 9. (a) Secretion of IL-12 by BMDCs incubated with acid-
degradable 10% cationic nanoparticles coated with unmethylated
CpG oligonucleotide (CpG ODN) and (b) IL-10 secretion by
BMDCs incubated with 10% cationic nanoparticles coated with
anti-IL-10 oligonucleotides (AS10 ODN) for 24 h.was adsorbed onto the cationic acid-degradable nano-
particles. The secretion of IL-10, an antagonist cyto-
kine to IL-12, by BMDCs was inhibited by delivery of
AS10 ODN. A 60% decrease in IL-10 secretion was
observed when the oligonucleotide was combined
with cationic nanoparticles (Fig. 9b). Therefore, the
formulation of acid-degradable cationic nanoparticles
can be tuned to produce the maximum CTL-mediated
immune response by stimulating IL-12 secretion and
inhibiting IL-10 expression by DCs.4. Discussion
Numerous interesting studies have been carried
out since vaccines have been reconsidered as a
preventive and therapeutic tool against cancer, one
of the major causes of death in western societies.
However, it was discovered that simply injecting
cancer antigens was not sufficient to activate an
anti-cancer immune response, as not only cancer
cells but also normal cells express the same antigen
(i.e., cancer-associated antigen) [5]. Frequently, can-
cer cells downregulate MHC molecules so that ex-
pression of cancer antigens is insufficient [23]. Once
established, cancer cells also secrete cytokines and
form new rigid tumor tissue as a defense against
immune attack [24]. Therefore, developing an effi-
cient cancer vaccine is urgently needed. As more
knowledge and understanding of cancer becomes
available, and as more unique cancer antigens are
identified, the design of an effective antigen delivery
vehicle becomes more critical. The ideal carrier
should possess the properties of specific targeting,
efficient antigen delivery, activation of proper im-
mune responses, facile and inexpensive preparation,
and simple administration and storage.
In this study, acid-degradable cationic nanoparti-
cles have been used to deliver a model antigen, oval-
bumin, to BMDCs. More evidence has been
accumulated indicating that DCs play pivotal roles
in orchestrating immune responses: activation and
tolerance [25,26]. DCs reside in antigen-encountering
areas, such as under the skin and the mucosal layer.
After antigen uptake and maturation, DCs migrate to
lymphoid organs such as the spleen and lymph nodes
and activate naı¨ve T and B cells by very efficiently
presenting antigen-derived peptides with costimula-
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at high concentrations upon activation [27,28]. DCs
are also more susceptible than other cells to viral
infections like human inmmunodeficiency virus type
1 (HIV-1) and severe acute respiratory syndrome
(SARS) coronavirus so that viral antigens are pre-
sented efficiently [29,30]. It has also been shown
that DCs link innate immunity with adaptive immu-
nity. Therefore, it is a general consensus that the
targeting and priming of DCs is a critical target for
the development of a successful vaccine strategy.
It was demonstrated that acid-degradable nano-
particles are significantly more effective in antigen
presentation by MHC I than non-degradable nano-
particles (Fig. 4). A possible explanation for this
finding is that more proteins are released into cyto-
plasmic space with the acid-degradable particles
than is the case with the non-degradable ones. It
was previously hypothesized that release of the
small molecule aldehyde after hydrolysis might de-
stabilize the lysosomal membrane due to increased
osmotic pressure [12], followed by cytosolic release
of the antigen. In addition, the swelling effect of the
hydrogel nanoparticles resulting from the cross-link-
er cleavage may also contribute to the more facile
release as swelling could lead to a leaky lysosomal
membrane structure. However, more studies must be
undertaken to clarify the cellular behavior of acid-
degradable particles since there is still a dearth of
supporting evidence for endosomal (or lysosomal)
escape of extracellular molecules. For example, it
was believed that a polycationic polymer (e.g., PEI)
aided in endosomal escape by the proton sponge
effect. However, this theory was recently criticized
by some studies with various protonated groups
indicating no difference in endosomal escape
[31,32]. As shown in Fig. 8, the degradability of
the particles favors distribution of the antigenic pay-
load throughout the cytoplasmic space, thereby con-
tributing to more efficient presentation of antigen-
derived peptides through DC maturation. Another
possible explanation of the enhanced antigen presen-
tation is the protection of proteins from lysosomal
degradation in the encapsulated microenvironment of
the nanoparticles, slowing or even negating the effect
of proteases and minimizing exposure to the degrad-
ing conditions of the lysosome as a result of fast
release into the cytoplasm. Therefore, more proteinswould be successfully processed in the cytoplasm
and presented on MHC I molecules.
Cationic molecules are well known to be easily
internalized by most cells, including phagocytes such
as macrophages and DCs, due to the attractive inter-
actions with negatively charged proteoglycans on the
cell surface [33,34]. It has also been shown that
relatively large cationic particles, even as large as a
few microns in diameter, could be taken up by DCs
very efficiently [35,36]. Our cationic nanoparticles are
designed to be efficiently endocytosed to help in-
crease delivery efficiency since the more antigen pro-
teins are delivered, the more antigen-derived peptides
will be presented, therefore increasing the probability
of encounter with T cells.
A drawback with cationic molecules is their cyto-
toxicity and therefore the amount administered must
be kept to a minimum, which may result in low
efficiency. However, it was demonstrated in this
study that the cationic nanoparticles could deliver
ovalbumin more efficiently than neutral ones while
the toxicity of the two types of nanoparticles remained
comparable at low concentration (i.e., 25–50 Ag in
200 AL).
In addition to the advantage of using a cationic
carrier for increased endocytosis, the cationic surface
of the particle can adsorb anionic molecules such as
DNA and negatively biased proteins. In previous
studies, polylactide-co-glycolic acid (PLGA) particles
coated with cationic surfactant effectively adsorbed
plasmid DNA and oligonucleotides [37–39]. It was
also shown that GM-CSF, which has isoelectric points
of 4.6–4.9, was adsorbed and delivered on cationic
particles [40]. The nanoparticles used in this study
have also demonstrated the ability to adsorb negative-
ly charged DNA and the cationic surface ratio was
easier to modulate with these nanoparticles than was
the case with previously reported systems.
Due to the progress in immunology, it has been
revealed that an immune response is the result of the
cell–cell interactions in very complicated networks
under strict control. This response is mediated by
surface molecules (e.g., receptors) and/or secreted
macromolecules (e.g., cytokines). Once an unmethy-
lated CpG DNA binds to TLR9 located under the cell
surface and migrates to an endosomal or lysosomal
compartment, APCs are activated to secrete cytokines
(e.g., IL-12) and to upregulate costimulatory surface
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that TLR also regulates the maturation of the phago-
some [43]. Therefore, delivering CpG DNA helps
CTL activation by upregulating costimulatory mole-
cules on the DC surface and encouraging the secretion
of TH1-polarizing IL-12. This directed immunostimu-
latory response can be maximized by suppressing
antagonistic IL-10 secretion, for example, which can
be accomplished by delivering antisense oligonucleo-
tides, as shown in this study (Fig. 9). Interestingly,
some studies have indicated that the cross-presenta-
tion—presentation of extracellular antigen by MHC
I—of CpG DNA-conjugated proteins was induced by
DCs [44,45]. This means that CpG DNA helps not
only to stimulate innate immunity but also amplifies
CTL-mediated immunity (or cellular immunity) rather
than humoral immunity by cytokine release and cross-
presentation. Therefore, it is expected that the cationic
nature of the acid-degradable nanoparticles used in
this study can be very useful as cancer vaccine carriers
capable of adjusting immune responses.5. Conclusions
Cationic acid-degradable nanoparticles can be used
as carriers of a model antigen-ovalbumin—for pro-
tein-based vaccine development. The enhanced MHC
I-mediated antigen presentation that is observed
appears to be related to the acid-degradability of the
particles. Cationic particles are endocytosed more
efficiently than neutral ones, although the amount
and cationic density of the particles requires optimi-
zation due to the innate cytotoxicity of cationic spe-
cies. Finally, maximized cellular immunity can be
achieved by delivering antigens with adjuvant nucleo-
tides adsorbed onto the cationic surface of the acid-
degradable particles.Acknowledgements
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